Zealand Pharma partner Boehringer Ingelheim initiates Phase 1 trials for diabetes/ obesity treatments
Zealand Pharma A/S has announced that their strategic collaboration partner, Boehringer Ingelheim, has initiated Phase 1 studies assessing candidates for the treatment of obesity and/or diabetes.
Two compounds invented through the Zealand and Boehringer Ingelheim research collaboration will be trialled: the novel compounds are a dual-acting glucagon/GLP-1 agonist and a long-acting amylin analog
Zealand will receive a EUR 4 million (DKK 30 million) milestone payment related to the initiation of Phase 1 with the long-acting amylin analog.
Results from the trials on both compounds are expected in late 2018.